Amgen INC 10-Q quarterly reports

Amgen Inc. announced robust third-quarter and year-to-date financial results, driven by significant product volume growth, despite increasing regulatory and market pricing pressures.

Amgen reports significant revenue and earnings growth in Q2 2025, driven by strong product volumes, while navigating increasing pricing pressures and ongoing legal challenges.

Amgen's Q1 2025 results show a 9% increase in total revenue, driven primarily by volume growth in key products.

Amgen's Q3 2024 results show a significant increase in revenue, primarily driven by the acquisition of Horizon Therapeutics and strong performance from key products, though operating expenses also rose substantially.

Amgen's second quarter 2024 results show a significant increase in revenue driven by the Horizon Therapeutics acquisition, but also a decrease in net income due to higher operating expenses and tax adjustments.

Amgen's first quarter results show a net loss driven by acquisition costs and investment losses, despite a significant increase in product sales.